Seta Clinic Group operates the following medical facilities and provides immuno-cell therapy to cancer patients.
For datailed informations, please contact us by e-mail. info@j-immunother.com

Immuno-cell therapy is a theoretically proved option of immunotherapy that immune cells are taken out of the body of a cancer patient, proliferated and activated strongly during culture outside of the body and then infused back to the body of the original patient.　Thus anti-cancer immune resistance of the patient is augumented.　Because reagents for stimulating the cells of immune system are used during culture outside of the body and washed out before the infusion, this therapy entails only minimal adverse effects.　Also, since patient's own materials (cells and blood plasma for culture) are used exclusively, this therapy is basically free from hazards such as undesirable immune reactions and infections caused by viral contaminations.

Although this method has limitations in the therapeutic effect just like other therapies for the progressive cancer, there have been cases that the disease becomes stable for a long period of time.　It is noteworthy that some statistical evidences have been presented showing that this therapy is carried out in combination with surgical removal of tumor, percentage of recurrence during long term follow up decreases significantly.

Immuno-cell therapy is classified into two types: (1)autologous activated lymphocyte therapy (formerly called adoptive immunotherapy) and (2)dendritiuc cell vaccine therapy, in which dendritic cells (a type of cells in the immune system that specialized in antigen-specific stimulation of lymphocytes) are utilized.

Seta clinic group provides the following variations of immuno-cell therapy.

1. Autologous activated lymphocyte therapy
a.	αβT-cell therapy (alpha-beta T-cell therapy)
		The lymphocyte population used for the therapy mainly contains T lymphocytes bearing T-cell receptor of αβ type.
b.	γδT-cell therapy (gamma-delta T-cell therapy)
		The lymphocyte poplation used for the therapy mainly contains T lymphocytes bearing T-cell receptor of γδ type.
c.	CTL therapy (cytotoxic T lymphocyte therapy)
		Lymphocytes are stimulated during culture with inactivated tumor cells obtained from pleural or peritoneal effusion of the patient and used for the therapy.
2. DC vaccine therapy (dendritic cell vaccine therapy)
	Dendritic cells are prepared from peripheral blood monocytes by in vitro differentiation, trated with protein fraction obtained from patient's own tumor or with antigenic fragment of tumor antigen and used for the therapy.
3. DC vaccine and αβT-cell therapy
	Combination of 1. and 2.